Intercept Didn't Disclose Cholesterol Data

Intercept Pharmaceuticals knew in January that the National Institutes of Health had halted a drug study because patients showed abnormal cholesterol levels, emails indicate.



from WSJ.com: US Business http://ift.tt/1ohkmjO

via IFTTT